menu search

genentech to present new key clinical and real-world data at ectrims-actrims 2023 showcasing strength of long-term outcomes in ms and nmosd

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

October 2, 2023, 1:00 am

Predicine announces new study published in the new england journal of medicine demonstrating clinical utility of its mrd liquid biopsy assay in supporting genentech’s phase 1 clinical trial of divaras

PredicineBEACON™ and PredicineWES+™ were used to detect and monitor a diverse spectrum of genomic alternations and emerging resistance mechanisms ...

September 20, 2023, 5:12 pm

Predicine announces new study published in the new england journal of medicine demonstrating clinical utility of its mrd liquid biopsy assay in supporting genentech’s phase 1 clinical trial of divaras

PredicineBEACON™ and PredicineWES+™ were used to detect and monitor a diverse spectrum of genomic alternations and emerging resistance mechanisms ...

September 20, 2023, 5:12 pm

Predicine announces new study published in the new england journal of medicine demonstrating clinical utility of its mrd liquid biopsy assay in supporting genentech’s phase 1 clinical trial of divaras

PredicineBEACON™ and PredicineWES+™ were used to detect and monitor a diverse spectrum of genomic alternations and emerging resistance mechanisms ...

September 20, 2023, 5:12 pm

Arcus biosciences: huge cash, gilead deal, not a lot of data

Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with...

August 29, 2023, 2:40 pm

Genprex shares rise as fda grants third fast track designation for small cell lung cancer therapeutic reqorsa

Genprex, Inc. (NASDAQ:GNPX) shares moved higher in pre-market trading after the clinical-stage gene therapy company announced that the US Food and Dru...

June 28, 2023, 9:31 am

Exelixis: thriving investment opportunity in the evolving world of oncology

Revenue-generating products like Cabometyx and strategic partnerships with industry leaders, such as genentech...

May 28, 2023, 5:49 am

Adaptive biotechnologies announces fda acceptance of genentech’s investigational new drug application for the first neoantigen-directed t-cell therapy product in oncology

The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discov...

May 9, 2023, 11:30 am

Factbox: bayer's new ceo: long-time roche, genentech executive, bill anderson

Bayer bowed to investor pressure on Wednesday and named Bill Anderson, most recently head of Roche's pharmaceuticals business, to take over from Werne...

February 8, 2023, 2:03 pm

Kronos bio's stock rallies after announcing drug-discovery deal with roche

Shares of Kronos Bio Inc. KRON, +2.38% jumped 25% in premarket trading on Monday after the company announced a development deal with Roche Holding's R...

January 9, 2023, 8:23 am

genentech to present scientific progress across alzheimer's disease pharmaceutical and diagnostic portfolio at 2022 aaic annual meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

July 28, 2022, 1:00 am

genentech to present data across broad and impactful neuroscience portfolio at 2022 aan annual meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

March 25, 2022, 2:00 am

Biogen exercises option to participate developing genentech's bispecific antibody, mosunetuzumab

Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispe...

February 1, 2022, 10:03 am

Biogen exercises option to participate developing genentech's bispecific antibody, mosunetuzumab

Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispe...

February 1, 2022, 10:03 am

Biogen exercises option to participate developing genentech's bispecific antibody, mosunetuzumab

Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispe...

February 1, 2022, 10:03 am

genentech's anti-amyloid beta antibody gantenerumab granted fda breakthrough therapy designation in alzheimer's disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

October 8, 2021, 4:48 pm

genentech's anti-amyloid beta antibody gantenerumab granted fda breakthrough therapy designation in alzheimer's disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

October 8, 2021, 4:48 pm

genentech's anti-amyloid beta antibody gantenerumab granted fda breakthrough therapy designation in alzheimer's disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

October 8, 2021, 4:48 pm

Ad hoc announcement pursuant to art. 53 lr: genentech's anti-amyloid beta antibody gantenerumab granted fda breakthrough therapy designation in alzheimer's disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

October 8, 2021, 11:40 am

Ad hoc announcement pursuant to art. 53 lr: genentech's anti-amyloid beta antibody gantenerumab granted fda breakthrough therapy designation in alzheimer's disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--genentech, a member of the Roche Group (SIX: RO, ROG; OTC...

October 8, 2021, 11:40 am


Search within

Pages Search Results: